Scholarlink

Background <p>Intravesical onabotulinumtoxinA (BTX-A) injection is an established treatment for overactive bladder (OAB) in patients who do not respond to conventional medical therapy. This study aimed to evaluate the safety and efficacy of BTX-A injections in patients with urinary dysfunction after radical prostatectomy (RP).</p> Methods <p>This retrospective case series included 11 post-RP patients with urinary dysfunction　who received intravesical BTX-A injections and were followed-up for 12&#xa0;months. We measured and analyzed the efficacy of BTX-A treatment using the Overactive Bladder Symptom Score (OABSS), International Prostate Symptom Score (IPSS), quality of life score, and number of pad sheets used before and after intravesical BTX-A injection.</p> Results <p>Following BTX-A injections, significant improvements were observed in the OABSS Q2 score, which evaluates nocturia. The median (IQR) OABSS Q2 score improved from 3.0 (2.0–3.0) at baseline to 1.0 (1.0–2.0, <i>p</i> = 0.012) at 3&#xa0;months. Similarly, the IPSS Q7 score showed notable changes. The baseline median (IQR) was 3.0 (2.0–4.0), which significantly reduced to 2.0 (2.0–2.5, <i>p</i> = 0.036) at 1&#xa0;month. Further improvement was observed at 3&#xa0;months, with a median (IQR) of 2.0 (1.0–2.5, <i>p</i> = 0.021). There were no statistically significant differences in the other categories. There were no statistically significant differences among the other categories.</p> Conclusion <p>Intravesical BTX-A injections significantly improved nocturia without complications in post-RP patients. This treatment represents a potential therapeutic option for managing refractory nocturia after RP.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Possible therapeutic effect on nocturia after radical prostatectomy by OnabotulinumtoxinA injection: a case series

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月20日

查看全文
  • Naoki Imasato,
  • Shugo Yajima,
  • Ryo Andy Ogasawara,
  • Kohei Hirose,
  • Ken Sekiya,
  • Sao Katsumura,
  • Madoka Kataoka,
  • Yasukazu Nakanishi,
  • Hitoshi Masuda

摘要

Background

Intravesical onabotulinumtoxinA (BTX-A) injection is an established treatment for overactive bladder (OAB) in patients who do not respond to conventional medical therapy. This study aimed to evaluate the safety and efficacy of BTX-A injections in patients with urinary dysfunction after radical prostatectomy (RP).

Methods

This retrospective case series included 11 post-RP patients with urinary dysfunction　who received intravesical BTX-A injections and were followed-up for 12 months. We measured and analyzed the efficacy of BTX-A treatment using the Overactive Bladder Symptom Score (OABSS), International Prostate Symptom Score (IPSS), quality of life score, and number of pad sheets used before and after intravesical BTX-A injection.

Results

Following BTX-A injections, significant improvements were observed in the OABSS Q2 score, which evaluates nocturia. The median (IQR) OABSS Q2 score improved from 3.0 (2.0–3.0) at baseline to 1.0 (1.0–2.0, p = 0.012) at 3 months. Similarly, the IPSS Q7 score showed notable changes. The baseline median (IQR) was 3.0 (2.0–4.0), which significantly reduced to 2.0 (2.0–2.5, p = 0.036) at 1 month. Further improvement was observed at 3 months, with a median (IQR) of 2.0 (1.0–2.5, p = 0.021). There were no statistically significant differences in the other categories. There were no statistically significant differences among the other categories.

Conclusion

Intravesical BTX-A injections significantly improved nocturia without complications in post-RP patients. This treatment represents a potential therapeutic option for managing refractory nocturia after RP.